Dr. Ming Jiang 蒋明
Chief Physician, Associate Professor
Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for lymphoma, breast cancer, and lung cancer, including chemotherapy, targeted therapy, and immunotherapy.
Dr. Jiang holds a PhD and serves as Chief Physician and Associate Professor at West China Hospital. After graduating from West China University of Medical Sciences in 1996, Dr. Jiang joined the hospital staff. Clinical work focuses on comprehensive medical treatment for malignancies, with expertise in chemotherapy, targeted therapy, and immunotherapy for lymphoma and breast cancer.
Professional roles
- Member, Chemotherapy Committee, Sichuan Anti-Cancer Association
- Member, Lymphoma Committee, Sichuan Anti-Cancer Association
- Member, Lymphatic and Hematologic Branch, National Geriatrics Society
Name order: in Chinese the family name comes first (Jiang Ming). Papers usually list the name as Ming Jiang or Jiang M.
Selected publications
82 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Cancer Res Clin Oncol, 2025 (senior author): Efficacy and safety of the R2-MTX regimen in primary central nervous system lymphoma (PCNSL): a single-center retrospective analysis. PubMed 40402307
- Front Pharmacol, 2024 (senior author): Case report: Tocilizumab for hypersensitivity reaction after oxaliplatin in a patient with NK/T-cell lymphoma. PubMed 39881879
- Front Oncol, 2024 (senior author): Case report: Good response to CMOP regimen containing mitoxantrone hydrochloride liposome (PLM60) as induction chemotherapy in patients with angioimmunoblastic T-cell lymphoma. PubMed 38357199
- Front Public Health, 2021 (senior author): Current Status of Out-of-Hospital Management of Cancer Patients and Awareness of Internet Medical Treatment: A Questionnaire Survey. PubMed 34970526
- Front Immunol, 2021 (senior author): Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review. PubMed 34566950
- J Cancer, 2021 (senior author): WFDC Protein: A Promising Diagnosis Biomarker of Ovarian Cancer. PubMed 34405003
- J Cancer Res Clin Oncol, 2019 (senior author): PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma. PubMed 31485768
- Oncotarget, 2017 (first author): A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma. PubMed 28404973
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion